dc.contributor.author | Ozturk, N. | |
dc.contributor.author | Öztürk, Deniz | |
dc.contributor.author | Okyar, Alper | |
dc.contributor.author | Pala-Kara, Zeliha | |
dc.date.accessioned | 2021-03-05T14:04:29Z | |
dc.date.available | 2021-03-05T14:04:29Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Ozturk N., Öztürk D., Pala-Kara Z., Okyar A., "Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation", PHARMAZIE, cilt.72, ss.29-34, 2017 | |
dc.identifier.issn | 0031-7144 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_b54e109e-ed53-41a5-a6f7-d26978e1cb7c | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/120722 | |
dc.identifier.uri | https://doi.org/10.1691/ph.2017.6786 | |
dc.description.abstract | Concomitant administration of P-glycoprotein substrates and inhibitors may cause pharmacokinetic drug interactions leading to increased concentrations associated with serious side effects and toxicities. Barnidipine is a long acting calcium-channel blocker and potent inhibitor of P-glycoprotein in vitro, and talinolol is a beta-blocker and probe substrate of P-glycoprotein. This study was designed to investigate the effects of single and repeated oral doses of barnidipine on talinolol pharmacokinetics in rats. In the single-dose study, talinolol (20 mg/kg) alone and with barnidipine at low (1 mg/kg) and high doses (10 mg/kg) were orally administered to rats. In the repeated-dose study, rats were treated with barnidipine (1 mg/kg/day) or vehicle only for four days, then with talinolol (20 mg/kg, on day 5). Blood samples were collected at 0.5, 1, 2, 4, 6 h following last dose and plasma talinolol levels were determined by HPLC. Compared to the control, C-max of talinolol elevated 10% (p=0.79) and 110% (p<0.05); plasma AUC(0.6h) increased 33% (p=0.41) and 46% (p<0.05) following low and high single doses of barnidipine co-administration, respectively. In the repeated-dose study, C-max and AUC(0-6h) of talinolol increased 131% (p<0.05) and 130% (p<0.05) respectively, following co-administration of a low barnidipine dose. Double-peaks were observed when single or repeated low doses of barnidipine were co-administered. There may be coupling between occurrence of double-peak phenomenon and P-glycoprotein inhibition. Increment of talinolol bioavailability upon low and high doses of barnidipine co-administration may be due to P-glycoprotein inhibition. The higher increase of talinolol plasma AUC(0-6h) due to the repeated doses of barnidipine may be explained by downregulation of P-glycoprotein. | |
dc.language.iso | eng | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Biyokimya | |
dc.subject | KİMYA, TIP | |
dc.subject | Temel Bilimler | |
dc.subject | Alkoloidler | |
dc.subject | Kimya | |
dc.subject | Temel Bilimler (SCI) | |
dc.subject | KİMYA, MULTİDİSİPLİNER | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Sağlık Bilimleri | |
dc.title | Pharmacokinetics of talinolol is modified by barnidipine: implication of P-glycoprotein modulation | |
dc.type | Makale | |
dc.relation.journal | PHARMAZIE | |
dc.contributor.department | İstanbul Teknik Üniversitesi , Gemi İnşaatı Ve Deniz Bilimleri , Gemi Ve Deniz Teknolojisi Mühendisliği | |
dc.identifier.volume | 72 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 29 | |
dc.identifier.endpage | 34 | |
dc.contributor.firstauthorID | 79270 | |